Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Neuronetics (NASDAQ: STIM) has announced the granting of inducement awards to new employees, approved by the Company's Board Compensation Committee under NASDAQ Listing Rule 5635(c)(4). The awards include Performance Restricted Stock Units (PRSUs) and Restricted Stock Units (RSUs) subject to the 2020 Inducement Incentive Plan.

The PRSUs will vest based on achieving cash flow breakeven targets: 25% for Q2 2025, 50% for Q3 2025, and 25% for Q4 2025. Key recipients include Bill Leonard (100,000 PRSUs), Andy Crish, Geoff Grammer, and Peter Willett (60,000 PRSUs each). RSUs were granted to multiple employees with various vesting schedules over 3-4 years.

Positive

• Company links executive compensation to cash flow breakeven targets, aligning management interests with financial performance
• Structured vesting schedule over multiple years encourages long-term employee retention

Negative

• Significant equity grants may lead to future shareholder dilution
• Cash flow breakeven not expected until at least Q2 2025, indicating current negative cash flow

MALVERN, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by the Compensation Committee of the Company’s Board of Directors and were made as material inducements to the recipients’ employment with the Company. In all cases, vesting is subject to the recipient’s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company’s 2020 Inducement Incentive Plan.

Performance restricted stock units (“PRSUs”)

Name	Number of PRSUs	Vesting Date
Bill Leonard	100,000	December 31, 2025
Andy Crish	60,000	December 31, 2025
Geoff Grammer	60,000	December 31, 2025
Peter Willett	60,000	December 31, 2025

25% of the award will be attained if the Company achieves cash flow breakeven for the fiscal quarter ended June 30, 2025, 50% of the award will be attained if the Company achieves cash flow breakeven for the fiscal quarter ended September 30, 2025, and 25% of the award will be attained if the Company achieves cash flow breakeven for the fiscal quarter ended December 31, 2025.

Restricted stock units (“RSUs”)

Name	Number of Inducement Plan RSUs	Vesting Schedule
Bill Leonard	100,000	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date
Bill Leonard	100,000	1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date; 1/3 on fourth anniversary of grant date
Andy Crish	33,750	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date
Andy Crish	33,750	1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date; 1/3 on fourth anniversary of grant date
Geoff Grammer	33,750	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date
Geoff Grammer	33,750	1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date; 1/3 on fourth anniversary of grant date
Peter Willett	33,750	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date
Peter Willett	33,750	1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date; 1/3 on fourth anniversary of grant date
Latoya Blaylock	24,000	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date
Latoya Blaylock	16,000	1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date; 1/3 on fourth anniversary of grant date
Annie Farley	24,000	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date
Annie Farley	16,000	1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date; 1/3 on fourth anniversary of grant date
Thomas Harris	24,000	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date
Thomas Harris	16,000	1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date; 1/3 on fourth anniversary of grant date
Nicole Lowry	24,000	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date
Nicole Lowry	16,000	1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date; 1/3 on fourth anniversary of grant date
Bryce Newmann	24,000	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date
Bryce Newmann	16,000	1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date; 1/3 on fourth anniversary of grant date
Egan Pratt	24,000	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date
Egan Pratt	16,000	1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date; 1/3 on fourth anniversary of grant date

About Neuronetics and Greenbrook

Neuronetics, Inc. (“Neuronetics”) believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations by offering exceptional treatments that produce extraordinary results. Neuronetics’ NeuroStar Advanced Therapy for Mental Health is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar system and associated treatment sessions to customers, Greenbrook TMS Inc. (“Greenbrook”) operates treatment centers across the United States, offering both NeuroStar Advanced Therapy (transcranial magnetic stimulation or “TMS”) and Spravato® (esketamine nasal spray) for the treatment of major depressive disorder (“MDD”) and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with more than 6.9 million treatments delivered and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Spravato® is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. Greenbrook has provided more than 1.68 million treatments to over 51,000 patients struggling with depression.

Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com

Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com

FAQ

What are the cash flow breakeven targets for STIM's PRSU vesting in 2025?

The PRSUs will vest based on achieving cash flow breakeven: 25% for Q2 2025, 50% for Q3 2025, and 25% for Q4 2025.

How many PRSUs did Neuronetics (STIM) grant to Bill Leonard?

Bill Leonard was granted 100,000 Performance Restricted Stock Units (PRSUs) that vest on December 31, 2025.

What is the vesting schedule for STIM's new RSU grants?

The RSUs have varying vesting schedules, with some vesting 1/3 annually over three years and others vesting 1/3 annually over four years from the grant date.

How many treatments has Neuronetics' NeuroStar system delivered for depression?

NeuroStar Advanced Therapy has delivered more than 6.9 million treatments and is backed by the largest clinical data set of any TMS treatment system for depression.